Updates are available Correction dated 2023-12-05
Click to view Correction: https://doi.org/10.1038/s41569-023-00974-z
-
Authors
Galli, Mattia
Niccoli, Giampaolo
De Maria, Gianluigi http://orcid.org/0000-0003-3572-1855
Brugaletta, Salvatore
Montone, Rocco A. http://orcid.org/0000-0002-6439-1018
Vergallo, Rocco
Benenati, Stefano
Magnani, Giulia
D’Amario, Domenico
Porto, Italo http://orcid.org/0000-0002-9854-5046
Burzotta, Francesco
Abbate, Antonio http://orcid.org/0000-0002-1930-785X
Angiolillo, Dominick J. http://orcid.org/0000-0001-8451-2131
Crea, Filippo
- License Information
-
More Information
Article History
Accepted: 23 October 2023
First Online: 24 November 2023
Change Date: 5 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41569-023-00974-z
Competing interests
: M.G. has received speaker fees from Terumo. G.D.M. has received research grants from Medtronic, Opsens, Philips and Terumo. I.P. has received consultant or speaker fees from Abbott, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Medtronic, Philips, PIAM, Sanofi and Terumo. F.B. has received speaker fees from Abbott, Abiomed, Medtronic and Terumo. A.A. has received consulting fees or honoraria from Implicit Biosciences, Kiniksa, Novo Nordisk, Olatec and Serpin Pharma. D.J.A. has received consulting fees or honoraria from Abbott, Amgen, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, PhaseBio, PLx Pharma, Pfizer, Sanofi and Vectura. D.J.A.’s institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis and the Scott R. MacKenzie Foundation. The other authors declare no competing interests.
